Recent studies have elucidated the mechanism by which the activation of GLP-1R alleviates osteoarthritis (OA), providing evidence that farnesoid X receptor (FXR) serves as a viable therapeutic target for this purpose through the enhancement of GLP-1 levels. This evidence concerns the gene GLP1R and osteoarthritis.